- Home
- PHIO vs QNRX Comparison
PHIO vs QNRX Comparison
Compare PHIO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHIO | QNRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 14.5M |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PHIO | QNRX |
|---|---|---|
| Price | $1.19 | $8.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 21.2K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.21 |
| 52 Week High | $4.19 | $41.80 |
Technical Indicators
Market Signals| Indicator | PHIO | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 48.37 |
| Support Level | $1.03 | $8.03 |
| Resistance Level | $1.21 | $10.05 |
| Average True Range (ATR) | 0.12 | 0.74 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 27.91 | 30.42 |
Price Performance
Historical ComparisonAbout PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.